Minor stroke as singular manifestation of hereditary thrombotic thrombocytopenic purpura in a young man

International Angiology

Volumn 28, Issue 4, 2009, Pages 336-339

  Lindblom, A ^a   Thorsen, S ^b   Hillarp, A ^a   Bjork P ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c Malmö University Hospital   (Sweden)

Author keywords

ADAMTS13 protein, human, deficiency; Purpura, thrombotic thrombocytopenic; Stroke

Indexed keywords

PLASMA SUBSTITUTE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN;

ADULT; ANEMIA; ARTICLE; CASE REPORT; DISEASE EXACERBATION; HUMAN; LABORATORY TEST; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; STROKE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; BLOOD; CHRONIC DISEASE; COMPLICATION; DEFICIENCY; GENETICS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENT DISEASE; THROMBOCYTE COUNT; TIME; TREATMENT OUTCOME;

ADAM PROTEINS; ADULT; CHRONIC DISEASE; HUMANS; MALE; PLASMAPHERESIS; PLATELET COUNT; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 70350491997     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Moschowitz, E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Arch Int Med 1925;36:89-93.
2. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600.
3. Furlan M, Robles R, Lämmle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo preoteolysis. Blood 1996;87:4223-4234 (Pubitemid 26152266)
4. Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-4244
5. Peyvandi F, Ferrari S, Lavoretano S, Canciani MT, and Mannuci PM. Von Willebrand cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura. Br J Haematol 2004;127:422-439 (Pubitemid 39536596)
6. Böhm M, Betz C, Miesbach W, Krause M, von Auer C, Geiger H et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 2005;129:644-652 (Pubitemid 40825826)
7. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005;129:93-100. (Pubitemid 40524057)
8. Böhm M, Vigh T, Scharrer I. Evaluation and clinical application of a new method for measuring activity of von Willebrand factor-cleaving metalloprotease (ADAMTS13). Ann Hematol 2002;81:430-435 (Pubitemid 36067656)
9. Krieg S, Studt J-D, Sulzer I, Lämmle B, Kremer Hovinga JA. Is factor V Leiden a risk factor for thrombotic microangiopathy without severe ADAMTS13 deficiency? Thromb Haemost 2005;94:1186-1189
10. Manea M, Kristoffersson A, Tsai HM, Zhou W, Winqvist I, Oldaeus G et al. ADAMTS 13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr 2007;166:249-257 (Pubitemid 46352518)
11. Banno F, Kokame K, Okuda T, Honda S, Miyata S, Kato H et al. Complete deficiency in ADAMTS 13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 2006;107:3161-3166